PR-364增强Parkin介导的线粒体自噬改善心肌梗死后左室重构
本研究探讨选择性小分子Parkin激活剂PR-364对心肌梗死后左室重构的作用。在体外心肌细胞模型和小鼠心梗模型中,单次腹腔注射PR-364可减少死亡率、保护射血分数并延缓心衰进展,机制涉及增强线粒体自噬与生物合成。
要点
- PR-364是选择性小分子Parkin激活剂,心梗后2小时单次腹腔注射给药。
- PR-364减少心梗后死亡率、保护心脏射血分数并延缓心衰进展。
- 机制涉及增强线粒体自噬、线粒体生物合成及代谢重编程。
核心结论
- 靶向Parkin介导的线粒体自噬(PR-364)具有保护心梗后存活心肌、延缓心衰进展的治疗潜力。
研究设计与样本
- 研究采用体内小鼠心肌梗死模型和体外心肌细胞模型,结合多组学策略与经典功能实验。
- PR-364于心梗后2小时单次腹腔注射给药。
主要发现
- 体外细胞数据显示PR-364激活Parkin后增加线粒体自噬和线粒体生物合成。
- PR-364改善三羧酸循环以增强三磷酸腺苷生成,改变线粒体钙定位积累并启动翻译重编程。
- 小鼠心梗后给予PR-364引起广泛蛋白质组变化,提示存活心肌中线粒体代谢和线粒体翻译上调。
- PR-364降低死亡率、保护心脏射血分数并减轻心衰进展。
临床怎么用
- PR-364作为Parkin激活剂,可能为心梗后保护存活心肌、预防心衰进展提供新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated myocardium. METHODS: This study has shown that a single i.p. dose (2 h post-MI) of the selective small molecule Parkin activator PR-364 reduced mortality, preserved cardiac ejection fraction, and mitigated the progression of HF. To reveal the mechanism of PR-364, a multi-omic strategy was deployed in combination with classical functional assays using in vivo MI and in vitro cardiomyocyte models. RESULTS: In vitro cell data indicated that Parkin activation by PR-364 increased mitophagy and mitochondrial biogenesis, enhanced adenosine triphosphate production via improved citric acid cycle, altered accumulation of calcium localization to the mitochondria, and initiated translational reprogramming with increased expression of mitochondrial translational proteins. In mice, PR-364 administered post-MI resulted in widespread proteome changes, indicating an up-regulation of mitochondrial metabolism and mitochondrial translation in the surviving myocardium. CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.
引用
- Ai, de Freitas Germano, Huang, et al. Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364. Eur Heart J. 2025. PMID: 39601359. doi:10.1093/eurheartj/ehae782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。